Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Samuel Martyn-Smith

DPhil Student

Biography

I completed my undergraduate degree in Biological and Medicinal Chemistry at the University of Exeter, where I graduated at the top of my class in 2020, and was awarded the Henderson-Ross Award for my work. During the second year of my undergraduate degree, I interned in Prof. Patrick Laprise's Lab in Quebec City. My work centred on characterising protien oligomerisation, and how this can promote the Epithelial-Mesenchymal transition and therefore promote metastasis. 

Following my undergraduate degree, I moved to the University of Cambridge and completed a MPhil in Infection Biology and Molecular Immunology. Here, I joined the Halim lab at the CRUK CI and investigated the way in which Group 2 Innate Lymphoid Cells can influence the spatial organisation of the TME in PDAC. Here, I gained experience in immunofluorescence staining, microscopy and quantifying immune niches and spatial distribution of immune cells within the TME. 

In October 2025, I joined Prof. Wither's Lab, to undertake an iCASE project entitled "Understanding the effect of combined immune checkpoint inhibition through space and time". Here, in partnership with Astrazeneca, I will work to investigate the way in which a novel bisepcific antibody differs in its immune-modulartory effect in comparison to its monospecific counterparts. My work will employ GEMM to elucidate how different treatment protocols influence immune trafficking and egress within colorectal tumours. Ultimately, I aim to optimise immunotherapy regimens for ICB and to characterise how distinct therapeutic approaches reshape the immune landscape and modulate treatment responses in colorectal cancer.